The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
The firm said it will use the net proceeds for R&D, including the continued development of its Acuitas AMR gene panels.
The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.
The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
Samsung Biologics debuted last week in Seoul with the largest IPO in South Korea in years, according to the Associated Press.
The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.
Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.
A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.
In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more